


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	GOXALAPLADIB
PRONUNCIATION	gox a lap' la dib
THERAPEUTIC CLAIM	Treatment of atherosclerosis

CHEMICAL NAMES

- 1) 1,8-naphthyridine-1(4*H*)-acetamide, 2-[2-(2,3-difluorophenyl)ethyl]-*N*-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-*N*-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
- 2) 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl]-*N*-[1-(2-methoxyethyl)piperidin-4-yl]-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide
- 3) 2-{2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl}-*N*-{1-(2-methoxyethyl)piperidin-4-yl}-*N*-[[4'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl}acetamide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>40</sub> H <sub>39</sub> F <sub>5</sub> N <sub>4</sub> O <sub>3</sub>
MOLECULAR WEIGHT	718.8
TRADEMARK	Unknown as yet
MANUFACTURER	GlaxoSmithKline
<u>CAS</u> REGISTRY NUMBER	412950-27-7